Country: New Zealand
Bahasa: Inggeris
Sumber: Medsafe (Medicines Safety Authority)
Aripiprazole 15mg;
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Aripiprazole 15 mg
15 mg
Tablet
Active: Aripiprazole 15mg Excipient: Hyprolose Iron oxide yellow Lactose monohydrate Magnesium stearate Maize starch Microcrystalline cellulose
Blister pack, AL/AL - 5 tablets, 5 tablets
Prescription
Prescription
Otsuka Pharmaceutical Co Ltd
ABILIFY is indicated of the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.
Package - Contents - Shelf Life: Blister pack, Al/Al - 5 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 7 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 10 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 14 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 20 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 28 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 30 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 56 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 60 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 90 tablets - 3 years from date of manufacture stored at or below 30°C - Blister pack, Al/Al - 98 tablets - 3 years from date of manufacture stored at or below 30°C
2006-08-18
ABILIFY™ 1 ABILIFY™ 5mg, 10mg, 15mg, 20mg & 30mg tablet Aripiprazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ABILIFY. It does not contain all the available information. Some of the information contained in this leaflet may not apply to you. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ABILIFY against the benefits it is expected to have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What ABILIFY is used for ABILIFY is a trade name (manufacturer's name) for the medicine aripiprazole (Ari-pip-rah- zol). ABILIFY belongs to a group of medicines called antipsychotic agents which improve the symptoms of certain types of mental illness. ABILIFY is used to treat symptoms of schizophrenia. ABILIFY may be given to treat acute episodes of sustained upward mood swings (mania) in adult patients with Bipolar 1 Disorder. During mania, patients experience episodes of overactivity, elation or irritability. Schizophrenia is a mental illness with disturbances in thinking, feelings and behaviour. Bipolar disorder is a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. Your doctor may have prescribed ABILIFY for another reason. Ask your doctor if you have any questions about why ABILIFY has been prescribed for you. There is no evidence that ABILIFY is addictive. This medicine is available only with a doctor's prescription. ABILIFY is not recommended for use in children under the age of 18, as safety and efficacy have not been established in this age group. Before you take ABILIFY When you must not take it Do not take ABILIFY if you have an allergy to: aripiprazole any of the ingredients listed at the Baca dokumen lengkap
New Zealand Data sheet NZ_DS_Abilify_V6.0_ February 2022 Page 1 of 34 1 ABILIFY TM TABLETS Abilify TM 5 mg, 10 mg, 15 mg, 20 mg & 30 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Aripiprazole. Each tablet contains 5 mg, 10 mg, 15 mg, 20 mg or 30 mg of aripiprazole. Excipient with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Abilify (aripiprazole) is available as: 5 mg blue, modified rectangular, shallow convex, bevel-edged, tablets, marked on one side with “A-007” and “5”; 10 mg pink, modified rectangular, shallow convex, bevel-edged, tablets, marked on one side with “A-008” and “10”; 15 mg yellow, round, shallow convex, bevel-edged, tablets, marked on one side with “A-009” and “15”; 20 mg white to pale yellowish white, round, shallow convex, bevel-edged, tablets, marked on one side with “A-010” and “20”; 30 mg pink, round, shallow convex, bevel-edged, tablets, marked on one side with “A-011” and “30”. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. Abilify monotherapy is indicated for acute and maintenance treatment of manic and mixed episodes with Bipolar I Disorder with or without psychotic features. Abilify is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features. 4.2 DOSE AND METHOD OF ADMINISTRATION _RECOMMENDED DOSAGE _ SCHIZOPHRENIA ADULTS The recommended starting dose for Abilify is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Doses in the range of 10 to 30 mg/day have been effective New Zealand Data sheet NZ_DS_Abilify_V6.0_ February 2022 Page 2 of 34 in clinical trials. Daily dosage may be adjusted on the basis of individual clinical status within the range of 10 to 30 mg daily. Dosage increases sho Baca dokumen lengkap